<DOC>
	<DOC>NCT01187667</DOC>
	<brief_summary>Haloperidol is prescribed in high risk ICU patients concerning delirium (50% or more chance to develop delirium detected with the delirium prediction model PRE-DELIRIC, or patients with history of dementia or alcohol abuse)since the delirium protocol is changed and haloperidol is added as a prevention treatment we are gathering information what the effect is on several aspects of delirium</brief_summary>
	<brief_title>Evaluation of Delirium Prevention in Critically Ill Patients</brief_title>
	<detailed_description>Measurement the effect of haloperidol as delirium preventive intervention. Determining effect on: - delirium incidence in the ICU - different subtypes of delirium - delirium free days in 28 days - days on the ventilator - length of stay on the ICU and In-Hospital - 28-day mortality - incidence of unexpected removal of tubes, and effect between different groups of patients. Safety of haloperidol concerning QT-time, extrapyramidal symptoms. Data are compared with the data of a historical cohort</detailed_description>
	<mesh_term>Critical Illness</mesh_term>
	<mesh_term>Delirium</mesh_term>
	<mesh_term>Haloperidol</mesh_term>
	<mesh_term>Haloperidol decanoate</mesh_term>
	<criteria>Patients With Predicted Delirium Chance of &gt;50% or history of dementia or alcohol abuse and treated with haloperidol CAMICU is Not Applicable Patients Admitted 24hours or Shorter on the ICU, Patients Who Are Delirious Within 24 Hours After ICU Admission patients whereby haloperidol is contraindicated</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>delirium</keyword>
	<keyword>prevention</keyword>
	<keyword>critical care</keyword>
	<keyword>haloperidol</keyword>
</DOC>